arrow
M

Massimo Milione

department of diagnostic pathology and laboratory medicine
H指数:54
被引数:9,553

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Deep molecular profiling of lung neuroendocrine tumours and supra-carcinoids

肺神经内分泌肿瘤和类癌的深层分子谱分析

2026-08-270
OA
Correction: MIF/CD74 axis is a target for novel therapies in colon carcinomatosis

更正:MIF/CD74轴是结肠癌腹膜转移的新型治疗靶点

2026-08-190
OAAI
Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center

液态活检用于评估和监测间变性甲状腺癌中的BRAF V600E:一项三级癌症中心的真实世界研究

2026-06-230
OAAI
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study

NIBIT-epi-meso研究中肿瘤DNA甲基化亚型预测胸膜间皮瘤患者的免疫治疗结果

2026-04-270
PRE
Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP)

活检样本在胃肠道肿瘤预后和预测性分析中的充分性标准与报告要求:意大利胃肠病理学家小组、意大利解剖病理学与细胞学学会分会(GIPAD-SIAPeC-IAP)立场文件

2026-04-011
OAAI
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial

Antonuzzo, L.; Lavacchi, D.; Spada, F.; Marconcini, R.; Gelsomino, F.; Amoroso, V.; Cosso, F.; Pellegrini, E.; Scolari, F.; Sparano, C.; 等. 依维莫司作为晚期神经内分泌肿瘤的维持疗法:来自MAVERIC II期试验的结果. Oncologist 2026, 31, oyaf432. [Google Scholar] [CrossRef] [PubMed]

2026-03-010
PRE
ASO Visual Abstract: Do Tumor Deposits Demand More? Association of Chemotherapy Regimen Intensity with Survival Outcomes in N1 Colon Cancer Patients with Tumor Deposits

ASO视觉摘要:肿瘤沉积需要更多吗?化疗方案强度与N1期结肠癌伴肿瘤沉积患者的生存结局的关联

2026-02-200
PRE
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期GEP-NENs的管理临床实践指南:意大利医学肿瘤学会(AIOM)与意大利神经内分泌肿瘤学会(ITANET)合作,采用GRADE方法进行证据评估和推荐。

2025-11-120
OAAI
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study

分子检测和精准肿瘤学对晚期甲状腺癌患者的影响:一项OrienTHYring真实世界研究

2025-10-290
OAAI
Digital Immunophenotyping of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Subtypes With Specific Tumor-Immune Microenvironment Features

肺不典型类癌和大细胞神经内分泌癌的数字免疫分型识别出具有特定肿瘤-免疫微环境特征的三个亚型

2025-10-240
OA
Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer

基因组不稳定性及CCNE1扩增作为分层高级别浆液性卵巢癌的新兴生物标志物

2025-08-070
OA
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma

II期PANDORA试验的设计与原理:晚期默克尔细胞癌的一线化疗免疫疗法

2025-06-120
OA
Clinicopathological Correlates of Hormone Expression-Based Subtypes of Non-Functioning Duodenal/Ampullary Neuroendocrine Tumors: A Multicenter Study of 151 Cases

基于激素表达分型的非功能性十二指肠/壶腹神经内分泌肿瘤的 clinicopathological 关联性:一项包含151例病例的多中心研究

2025-05-100
OA